Search results for "CoVID-19 vaccine"

showing 10 items of 61 documents

Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies

2021

AbstractThe availability of a COVID-19 vaccine has raised the issue of its compatibility with breastfeeding. Consequently, the Italian Society of Neonatology (SIN), the Italian Society of Pediatrics (SIP), the Italian Society of Perinatal Medicine (SIMP), the Italian Society of Obstetrics and Gynecology (SIGO), the Italian Association of Hospital Obstetricians-Gynecologists (AOGOI) and the Italian Society of Infectious and Tropical Diseases (SIMIT) have made an ad hoc consensus statement. Currently, knowledge regarding the administration of COVID-19 vaccine to the breastfeeding mother is limited. Nevertheless, as health benefits of breastfeeding are well demonstrated and since biological pl…

Position statementmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)BreastfeedingBreastfeedingConsensuHealth benefits03 medical and health sciences0302 clinical medicineObstetrics and gynaecology030225 pediatricsMedicalMedicineHumans030212 general & internal medicineVaccination.Societies Medicalbusiness.industryVaccinationlcsh:RJ1-570COVID-19lcsh:PediatricsBreastfeeding; COVID-19; Vaccination; COVID-19; Consensus; Female; Humans; Italy; Societies Medical; Breast Feeding; COVID-19 VaccinesSettore MED/38VaccinationBreast FeedingItalyFamily medicineCommentaryFemaleBiological plausibilitybusinessSocietiesBreast feedingHuman
researchProduct

COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis

2021

IntroductionThe World Health Organization declared the coronavirus disease 2019 (COVID-19) pandemic on March 11, 2020. Two vaccine types were developed using two different technologies: viral vectors and mRNA. Thrombosis is one of the most severe and atypical adverse effects of vaccines. This study aimed to analyze published cases of thrombosis after COVID-19 vaccinations to identify patients’ features, potential pathophysiological mechanisms, timing of appearance of the adverse events, and other critical issues.Materials and MethodsWe performed a systematic electronic search of scientific articles regarding COVID-19 vaccine-related thrombosis and its complications on the PubMed (MEDLINE) d…

Settore BIO/17 - Istologiamedicine.medical_specialtyImmunologyMEDLINEvaccine-related thrombosisSettore MED/43 - Medicina LegalePF4 antibodiesInternal medicinePandemicmedicineCOVID 19 Vaccine Vaccine ThrombosisImmunology and AllergyPlateletAdverse effectvaccine complicationsbiologybusiness.industryvaccine adverse effectsRC581-607medicine.diseaseThrombosisPathophysiologyVaccinationbiology.proteinSystematic ReviewImmunologic diseases. AllergyAntibodybusinessCOVID-19 vaccineFrontiers in Immunology
researchProduct

Differing kinetics of anti-spike protein IgGs and neutralizing antibodies against SARS-CoV-2 after Comirnaty (BNT162b2) immunization

2022

Abstract Aims Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection has had a serious worldwide impact on human health. On December 2020, an immunization campaign with a COVID-19 mRNA vaccine (Comirnaty-BNT162b2 Pfizer-BioNTech) was started in Italy, first targeting healthcare workers (HCWs). This study aims to investigate the antibodies that are response against SARS-CoV-2 vaccine. Methods and Results The kinetics and the persistence of both anti-S1/S2 IgGs and neutralizing antibodies (Nt-Abs) were investigated in 76 HCWs through a 4-month follow-up with multiple testing points starting at the first dose. Temporal analysis of SARS-CoV-2 Abs titre kinetics showed three diff…

Settore MED/07 - Microbiologia E Microbiologia ClinicaVaccines SyntheticCOVID-19 VaccinesSARS-CoV-2VaccinationCOVID-19General Medicineneutralizing antibodies.Settore MED/42 - Igiene Generale E ApplicataAntibodies ViralAntibodies NeutralizingApplied Microbiology and BiotechnologyKineticsItalyhealthcare workerImmunoglobulin GSpike Glycoprotein CoronavirusHumansmRNA Vaccineskinetics of antibodieBNT162 VaccineBiotechnologyJournal of Applied Microbiology
researchProduct

Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle…

2022

Background: This study aimed to investigate the early and longitudinal humoral response in Healthcare Workers (HCWs) after two doses of the BNT162b2 vaccine and to assess the association between metabolic and anthropometric parameters and the humoral response after vaccination. Methods: The study included 243 fully vaccinated HCWs: 25.50% previously infected with SARS-CoV-2 (with prior history of COVID-19—PH) and 74.40%—uninfected, seronegative before the first vaccination (with no prior history of COVID-19—NPH). IgG antibodies were measured, and sera were collected: prior to the vaccination, 21 days after the first dose, and 14 days and 8 months after the second dose. Res…

VaccinesCOVID-19 VaccinesSARS-CoV-2Health PersonnelMusclesCOVID-19Body Mass IndexInfectious DiseasesAdipose TissueMuscular DiseasesVirologyHumansIgG antibody; SARS-CoV-2; COVID-19; healthcare workers; health care professionals; COVID-19 vaccine; BNT162 vaccine; adipose tissue; body composition; immunizationRNA MessengerBNT162 VaccineViruses-Basel
researchProduct

Predicting COVID-19 booster vaccine intentions.

2022

Achieving broad immunity through vaccination is a cornerstone strategy for long-term management of COVID-19 infections, particularly the prevention of serious cases and hospitalizations. Evidence that vaccine-induced immunity wanes over time points to the need for COVID-19 booster vaccines, and maximum compliance is required to maintain population-level immunity. Little is known of the correlates of intentions to receive booster vaccines among previously vaccinated individuals. The present study applied an integrated model to examine effects of beliefs from multiple social cognition theories alongside sets of generalized, stable beliefs on individuals' booster vaccine intentions. US residen…

behavior changeand promotion of well-beingCOVID-19 VaccinesIntentionVaccine Relatedintegrated modelsClinical ResearchBehavioral and Social ScienceHumansPsychologyVaccinesPreventionrokotteetsosiaalinen kognitioVaccinationCOVID-19social cognition theoryPrevention of disease and conditionsrokotusGood Health and Well Being3.4 Vaccinesterveyskäyttäytyminenvaccine attitudes and beliefsvaccine hesitancyImmunizationrokotevastaisuus
researchProduct

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Ita…

2021

The coronavirus disease 2019 (COVID-19) pandemic has not finished yet, and the most promising option towards its ending is widespread vaccination. Because patients with inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC), often require immune-modifying treatment, which might increase the risk of opportunistic infection,1 their vaccination history for several infectious diseases is routinely checked, and when inadequate, vaccination is performed at diagnosis or ideally before immune suppressive treatment is started.1 However, IBD patients were not found to be at an increased risk of developing COVID-19 or of experiencing a more severe disease course.2

medicine.medical_specialty2019-20 coronavirus outbreakCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)IBDBrief Report - ClinicalInternal medicinemedicineHumansImmunology and AllergyIn patientAcademicSubjects/MED00260SARS-CoV-2business.industryVaccinationGastroenterologyCOVID-19Inflammatory Bowel DiseasesInflammatory Bowel DiseasesCOVID-19 Vaccines HumanVaccinationIBD Crohn Ulcerative Colitis Vaccination Covid 19 Sars-Cov 2COVID-19; COVID-19 vaccine; IBD; vaccine hesitancyvaccine hesitancybusinessCOVID-19 vaccineInflammatory Bowel Diseases
researchProduct

Cutaneous and Allergic reactions due to COVID‐19 vaccinations: A review

2021

ABSTRACT Introduction The pandemic caused by the novel coronavirus disease 2019 (COVID‐19) has had an unprecedented impact on the overall health and the global economy. Vaccination is currently the most dependable strategy to end the pandemic, despite the slower‐than‐hoped‐for rollout, particularly for low‐to‐middle‐income countries, and the uncertain duration of protection afforded by vaccination. The spike protein of the virus (immunodominant antigen of the virus) is the main target of the approved and candidate SARS‐CoV‐2 vaccines. This protein binds to the ACE2 receptor of the host cell, initiating the entry of the virus into the cell and the chain of subsequent events ending to Acute R…

medicine.medical_specialtyAllergyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ExacerbationReview ArticleDermatologyallergic reactionsmedicine.disease_causeSARS‐CoV‐2VirusAntigenCOVID‐19PandemicHypersensitivityHumansMedicineIntensive care medicineReview ArticlesCoronavirusbusiness.industryVaccinationCOVID-19cutaneous reactionsmedicine.diseaseVaccinationBNT162b2mRNA VaccinesbusinessJournal of Cosmetic Dermatology
researchProduct

Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives

2022

La pandemia por COVID-19 ha supuesto un reto para los países y sus profesionales sanitarios. La entrada viral en el hospedador a través del receptor ACE-2 y una activación excesiva del sistema inmunológico son claves para comprender tanto la incidencia como la gravedad de la enfermedad. La enfermedad inflamatoria intestinal (EII) representa una condición especial asociada con una respuesta descontrolada del sistema inmunológico a agentes externos. Los tratamientos para la EII se han asociado con un mayor riesgo de infecciones bacterianas y virales. Esto ha planteado la cuestión de una posible mayor incidencia y gravedad de la infección por COVID-19 en pacientes con EII. A lo largo de este a…

medicine.medical_specialtyCOVID-19 VaccinesIBD-treatmentCOVID-19 VaccinePopulationDiseaseIncidencia por COVID-19COVID-19 graveInflammatory bowel diseaseSulfasalazineInternal medicinetratamiento de la EIIPandemicmedicineHumansEnfermedad Inflamatoria Intestina (EII)Inflammatory Bowel Disease (IBD)educationSevere COVID-19Pandemicseducation.field_of_studyTofacitinibHepatologybusiness.industryVacuna COVID-19Incidence (epidemiology)GastroenterologyRevisadoCOVID-19General Medicinemedicine.diseaseInflammatory Bowel DiseasesVaccinationCOVID-19 incidenceTumor Necrosis Factor Inhibitorsbusinessmedicine.drugGastroenterología y Hepatología (English Edition)
researchProduct

An Insight into the Role of Postmortem Immunohistochemistry in the Comprehension of the Inflammatory Pathophysiology of COVID-19 Disease and Vaccine-…

2021

On 11 March 2020, the World Health Organization (WHO) declared a pandemic due to the spread of COVID-19 from Wuhan, China, causing high mortality rates all over the world. The related disease, which mainly affects the lungs, is responsible for the onset of Diffuse Alveolar Damage (DAD) and a hypercoagulability state, frequently leading to Severe Acute Respiratory Syndrome (SARS) and multiorgan failure, particularly in old and severe-critically ill patients. In order to find effective therapeutic strategies, many efforts have been made aiming to shed light on the pathophysiology of COVID-19 disease. Moreover, following the late advent of vaccination campaigns, the need for the comprehension …

medicine.medical_specialtyCOVID-19 VaccinesQH301-705.5AutopsyReviewDiseaseCatalysisInorganic ChemistryvaccinePandemicHumansMedicineEndotheliumBiology (General)Physical and Theoretical ChemistryIntensive care medicineDiffuse alveolar damageAdverse effectQD1-999Molecular BiologypathophysiologySpectroscopypostmortemChAdOx1 nCov-19SARS-CoV-2business.industryMechanism (biology)Organic ChemistryCOVID-19ThrombosisGeneral MedicinePathophysiologyComputer Science ApplicationsVaccinationChemistryimmunohistochemistryCytokinesAutopsybusinessInternational Journal of Molecular Sciences
researchProduct

Italian association for the study of the liver position statement on SARS-CoV2 vaccination.

2021

The vaccination campaign against Sars-CoV-2 commenced in Italy at the end of December 2020. The first ones to receive the immunization against the virus were the health workers and the residents of nursing homes, following which the vaccine would be available for the entire population, beginning with the most vulnerable individuals. SARS-CoV2 vaccines have been demonstrated to be safe for the general population, although no data for patients with liver diseases or those having undergone liver transplantation are available so far. The present position statement AISF is an attempt to suggest, based on the published data on the impact of Sars-Cov-2 infection in patients with chronic liver dise…

medicine.medical_specialtyCOVID-19 VaccinesSars-CoV-2medicine.medical_treatmentPopulationLiver transplantationChronic liver diseaseRisk AssessmentPatient safetyEpidemiologyMedicineChronic liver disease Sars-CoV-2 Vaccination Humans Immunosuppressive Agents Italy Liver Transplantation Patient Safety Patient Selection Risk Adjustment Risk Assessment SARS-CoV-2 Transplant Recipients Treatment Outcome COVID-19 COVID-19 Vaccines Immunization Programs Liver DiseasesHumanseducationeducation.field_of_studyHepatologybusiness.industryImmunization ProgramsLiver DiseasesPatient SelectionChronic liver disease; Sars-CoV-2; VaccinationVaccinationChronic liver diseaseGastroenterologyCOVID-19medicine.diseaseTransplant RecipientsLiver TransplantationVaccinationTreatment OutcomeImmunizationItalyFamily medicineChronic liver disease; Sars-CoV-2; Vaccination; Humans; Immunosuppressive Agents; Italy; Liver Transplantation; Patient Safety; Patient Selection; Risk Adjustment; Risk Assessment; SARS-CoV-2; Transplant Recipients; Treatment Outcome; COVID-19; COVID-19 Vaccines; Immunization Programs; Liver DiseasesRisk AdjustmentPatient SafetyPosition PaperbusinessRisk assessmentImmunosuppressive AgentsDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct